• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • AI Medical Devices and SaMDs: Classification Guidelines Released

AI Medical Devices and SaMDs: Classification Guidelines Released

Monday, 26 July 2021 / Published in Medical Device, News, NMPA Registration in China

AI Medical Devices and SaMDs: Classification Guidelines Released

On July 8, 2021, the China NMPA (National Medical Products Administration) announced (No. 47, 2021) the classification guidelines for artificial intelligence medical devices and SaMDs (Software as Medical Devices). This regulatory announcement covers standardized definitions of product attributes and applicable categories that can provide technical guidance to the medical device industry and regulatory authorities for product registration and registration renewal.

Highlights

At present, the AI software products in the medical field are mainly intended for data processing, decision support, etc., hence, the key factors for determining the product classification includes the intended use of the product and the algorithm maturity level.

According to the announcement, the definitions of Class II and Class III SaMDs are provided below:

Class III SaMDs

  • Used to assist in decision-making, such as the provision of lesion characteristics identification, lesion nature determination, medication guidance, treatment plan development and other clinical treatment recommendations

Class II SaMDs

  • Used for non-aided decision-making, such as data processing and measurement to provide clinical reference information, etc.

*Both classifications use algorithms with low maturity which means they are not previously listed in the market or the product safety and effectiveness is not yet proven.

This release continues NMPA’s close focus on SaMD including AI and machine learning products (see here for previous news).

By Colleen Xu and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Artificial Intelligence medical devices, SaMD

What you can read next

china yy standards
China YY Standards 2022 – New NMPA Updates Announced
Cisema announces Hamish King as new CEO
Cisema announces Hamish King as new CEO
CMDE Recruits Manufacturers of Biomaterials for Tissue Repair

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP